HC Wainwright & Co. Maintains Buy on Oruka Therapeutics, Raises Price Target to $70

Benzinga Newsdesk www.benzinga.com Positive 61.3%

Neg 0% Neu 0% Pos 61.3%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $40 to $70.